Vicente Planelles

Summary

Affiliation: University of Utah
Country: USA

Publications

  1. Spivak A, Bosque A, Balch A, Smyth D, Martins L, Planelles V. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients. Antimicrob Agents Chemother. 2015;59:5984-91 pubmed publisher
    ..The protein kinase C agonist ingenol 3,20-dibenzoate demonstrated significant promise in a rapid ex vivo assay using resting CD4(+) T cells from treated HIV-1-positive patients to measure latent HIV-1 reactivation. ..
  2. Macedo A, Resop R, Martins L, Szaniawski M, Sorensen E, Spivak A, et al. Influence of biological sex, age and HIV status in an in vitro primary cell model of HIV latency using a CXCR4 tropic virus. AIDS Res Hum Retroviruses. 2018;: pubmed publisher
  3. Szaniawski M, Spivak A, Cox J, Catrow J, Hanley T, Williams E, et al. SAMHD1 Phosphorylation Coordinates the Anti-HIV-1 Response by Diverse Interferons and Tyrosine Kinase Inhibition. MBio. 2018;9: pubmed publisher
    ..Tyrosine kinase inhibitors similarly induced SAMHD1 dephosphorylation, which protects macrophages from HIV-1 in a SAMHD1-dependent manner. SAMHD1 is a critical restriction factor regulating HIV-1 infection of macrophages. ..
  4. Spivak A, Planelles V. HIV-1 Eradication: Early Trials (and Tribulations). Trends Mol Med. 2016;22:10-27 pubmed publisher
    ..We review recent advances in pharmacologically based 'shock and kill' HIV-1 eradication strategies, including comparative analysis of early clinical trials. ..
  5. Spivak A, Larragoite E, Coletti M, Macedo A, Martins L, Bosque A, et al. Janus kinase inhibition suppresses PKC-induced cytokine release without affecting HIV-1 latency reversal ex vivo. Retrovirology. 2016;13:88 pubmed publisher
    ..The combination of ingenol compounds and JAK inhibition represents a novel strategy for HIV-1 eradication. ..
  6. Planelles V, Barker E. Roles of Vpr and Vpx in modulating the virus-host cell relationship. Mol Aspects Med. 2010;31:398-406 pubmed publisher
    ..This review describes the main functions ascribed to Vpr and Vpx in the context of both viral replication and modulation of host cell biology...
  7. Ramirez P, Famiglietti M, Sowrirajan B, DePaula Silva A, RODESCH C, Barker E, et al. Downmodulation of CCR7 by HIV-1 Vpu results in impaired migration and chemotactic signaling within CD4? T cells. Cell Rep. 2014;7:2019-30 pubmed publisher
    ..These results suggest that BST-2 and CCR7 may be downregulated via similar mechanisms. ..
  8. DePaula Silva A, Cassiday P, Chumley J, Bosque A, Monteiro Filho C, Mahon C, et al. Determinants for degradation of SAMHD1, Mus81 and induction of G2 arrest in HIV-1 Vpr and SIVagm Vpr. Virology. 2015;477:10-17 pubmed publisher
    ..We confirmed that HIV-1 Vpr induces degradation of Mus81 although, surprisingly, degradation is independent and genetically separable from Vpr׳s ability to induce G2 arrest. ..
  9. Ramirez P, DePaula Silva A, Szaniawski M, Barker E, Bosque A, Planelles V. HIV-1 Vpu utilizes both cullin-RING ligase (CRL) dependent and independent mechanisms to downmodulate host proteins. Retrovirology. 2015;12:65 pubmed publisher
    ..Therefore, potential therapies aimed at antagonizing the activities of Vpu may need to address these distinct mechanisms of action in order to achieve a maximal effect. ..

More Information

Publications11

  1. Bosque A, Nilson K, Macedo A, Spivak A, Archin N, Van Wagoner R, et al. Benzotriazoles Reactivate Latent HIV-1 through Inactivation of STAT5 SUMOylation. Cell Rep. 2017;18:1324-1334 pubmed publisher
    ..These compounds represent a different direction in the search for "shock and kill" therapies. ..
  2. Spivak A, Planelles V. Novel Latency Reversal Agents for HIV-1 Cure. Annu Rev Med. 2018;69:421-436 pubmed publisher
    ..This review describes current pharmacologic approaches to reactivate the latent reservoir so that infected cells can be recognized and targeted, with the ultimate goal of achieving an HIV-1 cure. ..